Literature DB >> 8294998

Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake.

X M Lu1, A J Fischman, S L Jyawook, K Hendricks, R G Tompkins, M L Yarmush.   

Abstract

UNLABELLED: Antisense oligodeoxynucleotides coupled to asialoglycoprotein carrier molecules were evaluated in terms of their ability to accumulate preferentially in the liver and thus potentially serve as an important method to regulate liver gene expression.
METHODS: Native and asialo-human alpha-1 acid glycoproteins were derivatized with low molecular weight poly(L)lysine and complexed with an antisense DNA (67 mer) complementary to the 5' end of rat serum albumin mRNA. The asialoglycoprotein antisense complex (conjugate) was characterized with respect to size, stability, and anti-sense loading, and the biodistribution of the conjugate was determined for normal rats at 5 min and 1, 6, and 24 hr after intravenous injection. In vivo stability of the anti-sense asialoglycoprotein complex was also evaluated using double-labeled (32P-antisense and 3H-glycoprotein) preparations.
RESULTS: The results of the conjugate characterization studies demonstrated that at least 30% of the anti-sense DNA dissociated from the carrier after 7 min under chromatographic conditions. When the conjugate was incubated with PBS, MEM or MEM plus 10% FBS for 1 hr at 37 degrees C, about 85% of the antisense DNA was dissociated from the carrier. The results of the biodistribution studies showed that the accumulation of the asialo-glycoprotein anti-sense complex in the liver was rapid and greatly exceeded the accumulation of the sialo-glycoprotein antisense analog or antisense alone.
CONCLUSION: These findings have significant implications for the targeted delivery of therapeutic antisense molecules to the liver.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8294998

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo.

Authors:  E A Biessen; H Vietsch; E T Rump; K Fluiter; J Kuiper; M K Bijsterbosch; T J van Berkel
Journal:  Biochem J       Date:  1999-06-15       Impact factor: 3.857

Review 2.  DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors.

Authors:  P D'Orléans-Juste; M G Sirois; E R Edelman; D Regoli; L H Pheng; G Bkaily; C J Lindsey
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

Review 3.  Application of antisense DNA method for the study of molecular bases of brain function and behavior.

Authors:  S Ogawa; D W Pfaff
Journal:  Behav Genet       Date:  1996-05       Impact factor: 2.805

4.  Scintigraphic imaging of oncogenes with antisense probes: does it make sense?

Authors:  J L Urbain; S K Shore; M C Vekemans; S C Cosenza; K DeRiel; G V Patel; N D Charkes; L S Malmud; E P Reddy
Journal:  Eur J Nucl Med       Date:  1995-06

Review 5.  Molecular conjugates: a targeted gene delivery vector for molecular medicine.

Authors:  R J Cristiano; J A Roth
Journal:  J Mol Med (Berl)       Date:  1995-10       Impact factor: 4.599

6.  A comparison between intravenous and peritoneal route on liver targeted uptake and expression of plasmid delivered by Glyco-poly-l-lysine.

Authors:  Chang-Qing Yang; Ji-Yao Wang; Guo-Ting Fang; Jian-Jun Liu; Jin-Sheng Guo
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

Review 7.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

8.  Uptake and distribution of fluorescein-labeled D2 dopamine receptor antisense oligodeoxynucleotide in mouse brain.

Authors:  S P Zhang; L W Zhou; M Morabito; R C Lin; B Weiss
Journal:  J Mol Neurosci       Date:  1996       Impact factor: 3.444

9.  Biodistribution of iodine-125 tyramine transforming growth factor alpha antisense oligonucleotide in athymic mice with a human mammary tumour xenograft following intratumoral injection.

Authors:  S Cammilleri; S Sangrajrang; B Perdereau; F Brixy; F Calvo; H Bazin; H Magdelenat
Journal:  Eur J Nucl Med       Date:  1996-04

10.  Distribution and anti-HBV effects of antisense oligodeoxynucleotides conjugated to galactosylated poly-L-lysine.

Authors:  Su-Jun Zheng; Sen Zhong; Jian-Jun Zhang; Feng Chen; Hong Ren; Cun-Liang Deng
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.